Estland - Estlands - Ravimiamet

boehringer ingelheim animal health france - marutaudi inaktiveeritud viirusvaktsiin - süstesuspensioon - 1rÜ 1ml 1ml 100tk

Estland - Estlands - Ravimiamet

g.l. pharma gmbh - eszopikloon - õhukese polümeerikattega tablett - 2mg 10tk; 2mg 30tk; 2mg 28tk; 2mg 20tk; 2mg 7tk; 2mg 50tk

Estland - Estlands - Ravimiamet

g.l. pharma gmbh - eszopikloon - õhukese polümeerikattega tablett - 1mg 14tk; 1mg 28tk; 1mg 20tk; 1mg 98tk; 1mg 30tk; 1mg 100tk; 1mg 10tk; 1mg 56tk

Estland - Estlands - Ravimiamet

ceva-phylaxia zrt. - veiste viirusdiarröa viirusvaktsiin - süstesuspensiooni lüofilisaat ja lahusti - 1annus 1tk; 50annus 1tk; 5annus 1tk; 10annus 1tk; 20annus 1tk

Estland - Estlands - Ravimiamet

g.l. pharma gmbh - eszopikloon - õhukese polümeerikattega tablett - 3mg 20tk; 3mg 98tk; 3mg 28tk; 3mg 100tk; 3mg 30tk; 3mg 10tk; 3mg 14tk; 3mg 50tk

Europese Unie - Estlands - EMA (European Medicines Agency)

les laboratoires servier - agomelatine - depressiivne häire, suur

Europese Unie - Estlands - EMA (European Medicines Agency)

les laboratoires servier - agomelatine - depressiivne häire, suur

Europese Unie - Estlands - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease (md) virus, serotype 1, strain rn1250 - immunoloogilised ained - kana - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus).

Europese Unie - Estlands - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease virus, serotype 1, strain rn1250; live recombinant turkey herpesvirus, expressing the vp2 protein of infectious bursal disease virus, strain vhvt013-69 - immunologicals for aves, domestic fowl, avian herpes virus (marek's disease) + avian infectious bursal disease virus (gumboro disease) + newcastle disease virus/paramyxovirus - kana - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus), and to prevent mortality, clinical signs and lesions caused by infectious bursal disease (ibd) virus.